BioVersys to present at H.C. Wainwright 28th Annual Global Investment Conference
Published on 09/03/2026 at 07:00 | dgap, AD HOC NEWS| BioVersys AG / Key word(s): Conference 03.09.2026 / 07:00 CET/CEST Basel, Switzerland. September 3, 2026, 7.00am CEST BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, held on September 14-16, 2026 in New York City, NY. BioVersys Session Presenter: Hernan Levett, Chief Financial Officer, BioVersys Date: September 16, 2026, 12.30pm – 1.00pm ET Location: Kennedy II (4th Floor), Lotte New York Palace, New York City, NY BioVersys On Demand Presenter: Dr. Marc Gitzinger, Chief Executive Officer, BioVersys Date: Live September 11, 2026 at 7.00AM ET; replay available for 90 days Webcast Link: Accessible on the H.C. Wainwright Platform or on the BioVersys website in the investor section. BioVersys' CEO and CFO will be available for meetings during the conference. Registered attendees can request one-on-one meetings with BioVersys by contacting their representative at H.C. Wainwright. About BioVersys BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. BioVersys contact Anca Cighi, Head of IR and Communication, Tel. +41 79 949 33 09; Mail: anca.cighi@bioversys.com For IR: IR@bioversys.com; Website: www.bioversys.com End of Media Release View original content: EQS News |
en | CH0210362643 | BIOVERSYS AG | boerse | 70046955 |
